Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Somatrogon (MOD-4023) in Healthy Volunteers
NCT02418767Phase 1Completed
- Sponsor
- OPKO Health
- Start
- Jan 2015
- Primary completion
- Mar 2015
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of somatrogon in growth hormone deficiency (GHD) (3 arms), sponsored by OPKO Health. Primary endpoints: Composite safety and tolerability parameters at 30 days and Pharmacokinetics profile of MOD-4023 at 7 days. Started Jan 2015; status: completed.
02
Drugs
somatrogon
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT02418767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02418767.